DNTH
Dianthus Therapeutics, Inc. /DE/
Next earnings Aug 5, 2026 · consensus $-0.89 EPS, $301K rev
Last earnings +1.0% on 2026-05-05
$90.80
▲ +3.74%$90.80▲ +420.64%
over 1Y
L $16.86EODHDH $95.76
Earnings Dividend Split Congress buy Congress sellGrouped by date · hover a pin to expand
Today+3.7%
1W+10.9%
1M+4.6%
3M+14.1%
YTD+128.8%
1Y+420.6%
Hold
Conviction
Horizon
Long (>12mo)
Street · 22 analysts
Strong Buy
Clinical-stage biotech with positive Phase 2 data and Phase 3 momentum, but pre-revenue, cash-burning and binary on trial outcomes.
Dianthus Therapeutics is a clinical-stage biotech developing complement and immune-pathway therapies for severe autoimmune diseases. Its lead candidate, claseprubart, is a selective C1s inhibitor engineered for convenient subcutaneous dosing, in mid-to-late-stage trials for generalized Myasthenia Gravis (gMG), CIDP, and MMN. The clinical news is genuinely encouraging: in September 2025 the company reported positive top-line Phase 2 MaGic data in gMG showing statistically significant, clinically meaningful improvements with a clean safety profile, held an end-of-Phase-2 FDA meeting, and plans to start a Phase 3 registrational trial in mid-2026 (top-line readout 2H2028). In March 2026 it announced an early 'GO' in the interim responder analysis of its Phase 3 CIDP CAPTIVATE trial — meaningful de-risking for an autoimmune-neurology pipeline.
Sources: SEC EDGAR (CIK 0001690585, latest 10-Q filed 2026-05-05) · EODHD · analysis by claude-code · as of 6/21/2026, 9:02:22 PM.
Research and education only — not financial advice. EDGAR is not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities EDGAR rates; see Disclosures. Past performance does not guarantee future results. Do your own research.